One case of extremely abnormal coagulation caused by warfarin combined with compound paracetamol and amantadine hydrochloride tablets

doi:10.19803/j.1672-8629.20220492

Abstract

Abstract: Objective To explore the possible adverse drug interactions between warfarin and compound paracetamol and amantadine hydrochloride tablets. Methods A patient who had been taking warfarin for a long time for venous sinus thrombosis was reported to have sustained extremely abnormal coagulation function after intermittent administration of compound paracetamol and amantadine hydrochloride tablets. Results The coagulation function of the patient recovered gradually after discontinuation of warfarin and supplementation of vitamin K and coagulation factors. Conclusion Compound paracetamol and amantadine hydrochloride tablets may significantly enhance the anticoagulant effect of warfarin, leading to an extremely high risk of bleeding. Clinicians should be alert to the interactions between the two drugs. Warfarin and cold medicine must be cautiously combined in clinical treatment, and bleeding and clotting function should be closely monitored.

Key words: warfarin, compound paracetamol and amantadine hydrochloride tablets, coagulation function, anticoagulation, adverse drug reaction, drug interaction

CLC Number:

R972
R994.11

ZHANG Wenwen, NIE Xiting, XU Huiru, RAN Ye, TIAN Chenglin, YU Shengyuan. One case of extremely abnormal coagulation caused by warfarin combined with compound paracetamol and amantadine hydrochloride tablets[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1290-1292.

References

[1] LIU S, SHEN G, LI W.Structural and cellular basis of vitamin K antagonism[J]. J Thromb Haemost, 2022, 20(9): 1971-1983.
[2] WANG M, ZERAATKAR D, OBEDA M, et al.Drug-drug interactions with warfarin: A systematic review and meta-analysis[J]. Br J Clin Pharmacol, 2021, 87(11): 4051-4100.
[3] TAN C, LEE S.Warfarin and food, herbal or dietary supplement interactions: a systematic review[J]. Br J Clin Pharmacol, 2021, 87(2): 352-374.
[4] VILLA ZL, HANSTEN PD, PANIC J, et al.Risk of bleeding with exposure to warfarin and nonsteroidal anti-inflammatory drugs: a systematic review and meta-analysis[J]. Thromb Haemost, 2020, 120(7): 1066-1074.
[5] LOPES RD, HOROWITZ JD, GARCIA DA, et al.Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility[J]. Blood, 2011, 118(24): 6269-6273.
[6] HUGHES GJ, PATEL PN, SAXENA N.Effect of acetaminophen on international normalized ratio in patients receiving warfarin therapy[J]. Pharmacotherapy, 2011, 31(6): 591-597.
[7] PINSON GM, BEALL JW, KYLE JA.A review of warfarin dosing with concurrent acetaminophen therapy[J]. J Pharm Pract, 2013, 26(5): 518-521.
[8] WISHART DS, FEUNANG YD, GUO AC, et al.DrugBank 5.0: a major update to the DrugBank database for 2018[J]. Nucleic Acids Res, 2017, 46(D1): D1074-D1082.
[9] ZAFAR S, ASHRAF MM, ALI A, et al.Effect of caffeine on anti-clotting activity of warfarin in healthy male albino rabbits[J]. Pak J Pharm Sci, 2018, 31(2Suppl): 611-616.
[10] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[11] CHUANTAO C, HUIHUI F, XIAOJUN F, et al.Individualized anticoagulant therapy for warfarin in a patient with poor metabolism[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(12): 939-942.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[7]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[8]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[9]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[10]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[11]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[12]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[13]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[14]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[15]	TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.